Development of a C3 Humanized Rat as a New Model for Evaluating Novel C3 Inhibitors
Authors:
- Jin Y. ChenJCJin Y. Chen
- Lingjun ZhangLZLingjun Zhang
- Maojing YangMYMaojing Yang
- Elizabeth D. HughesEHElizabeth D. Hughes
- Zachary T. FreemanZFZachary T. Freeman
- Thomas L. SaundersTSThomas L. Saunders
- Feng LinFLFeng Lin
Open Access
- 30 November 2023
- journal article
- research article
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 16 (1) , 56-65
Abstract
Introduction: C3 is central for all complement activation pathways, thus making it an attractive therapeutic target. Many C3-targeted agents are under extensive development with one already approved for clinical use. However, most, if not all, C3 inhibitors are human or nonhuman primate C3-specific, making evaluating their efficacies in vivo before a clinical trial extremely difficult and costly. Methods: We first studied the compatibility of human C3 in the rat complement system, then developed a C3 humanized rat using the CRISPR/Cas9 technology. We thoroughly characterized the resultant human C3 humanized rats and tested the treatment efficacy of an established primate-specific C3 inhibitor in a model of complement-mediated hemolysis in the C3 humanized rats. Results: We found that supplementing human C3 protein into the C3-deficient rat blood restored its complement activity, which was inhibited by rat factor H or compstatin, suggesting that human C3 is compatible to the rat complement system. The newly developed C3 humanized rats appeared healthy and expressed human but not rat C3 without detectable spontaneous C3 activation. More importantly, complement-mediated hemolysis in the C3 humanized rats was also inhibited by compstatin both in vitro and in vivo. Conclusion: The successfully developed C3 humanized rats provided a much-desired rodent model to evaluate novel C3 inhibitors in vivo as potential drugs.Keywords
This publication has 23 references indexed in Scilit:
- Complement System Part I – Molecular Mechanisms of Activation and RegulationFrontiers in Immunology, 2015
- Complement control protein factor H: The good, the bad, and the inadequateMolecular Immunology, 2010
- Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonizationHaematologica, 2010
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007
- Advances in transgenic rat productionTransgenic Research, 2006
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2006
- Complement Factor H Polymorphism in Age-Related Macular DegenerationScience, 2005
- Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3Molecular Immunology, 2003
- Hereditary C6 deficiency in a strain of PVG/c ratsClinical and Experimental Immunology, 1994
- Mouse strains with typical mammalian levels of complement activityJournal of Immunological Methods, 1989